rs778568339
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_003673.4(TCAP):c.26_33dupAGGTGTCG(p.Glu12fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000136 in 1,613,626 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000014 ( 0 hom. )
Consequence
TCAP
NM_003673.4 frameshift
NM_003673.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.08
Genes affected
TCAP (HGNC:11610): (titin-cap) Sarcomere assembly is regulated by the muscle protein titin. Titin is a giant elastic protein with kinase activity that extends half the length of a sarcomere. It serves as a scaffold to which myofibrils and other muscle related proteins are attached. This gene encodes a protein found in striated and cardiac muscle that binds to the titin Z1-Z2 domains and is a substrate of titin kinase, interactions thought to be critical to sarcomere assembly. Mutations in this gene are associated with limb-girdle muscular dystrophy type 2G. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 21 pathogenic variants in the truncated region.
PP5
Variant 17-39665382-G-GCGAGGTGT is Pathogenic according to our data. Variant chr17-39665382-G-GCGAGGTGT is described in ClinVar as [Pathogenic]. Clinvar id is 448649.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TCAP | NM_003673.4 | c.26_33dupAGGTGTCG | p.Glu12fs | frameshift_variant | 1/2 | ENST00000309889.3 | NP_003664.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TCAP | ENST00000309889.3 | c.26_33dupAGGTGTCG | p.Glu12fs | frameshift_variant | 1/2 | 1 | NM_003673.4 | ENSP00000312624.2 | ||
TCAP | ENST00000578283.1 | c.26_33dupAGGTGTCG | p.Glu12fs | frameshift_variant | 1/3 | 5 | ENSP00000462787.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152140
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000916 AC: 23AN: 251102Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135814
GnomAD3 exomes
AF:
AC:
23
AN:
251102
Hom.:
AF XY:
AC XY:
7
AN XY:
135814
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461486Hom.: 0 Cov.: 31 AF XY: 0.00000963 AC XY: 7AN XY: 727054
GnomAD4 exome
AF:
AC:
20
AN:
1461486
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
727054
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74308
GnomAD4 genome
AF:
AC:
2
AN:
152140
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74308
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 30, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 14, 2018 | The c.26_33dupAGGTGTCG variant in the TCAP gene has been reported in the homozygous state in a few unrelated individuals with LGMD2G (Waddell et a., 2012; Francis et al., 2014; Tian et al., 2015). This variant is not observed in large population cohorts (Lek et al., 2016). The c.26_33dupAGGTGTCG variant causes a shift in the reading frame starting at codon Glutamic acid 12, changing it to an Arginine, and creating a premature stop codon at position 20 of the new reading frame, denoted p.Glu12ArgfsX20. This variant is expected to result in a truncated protein product, in which the C-terminal 159 amino acids are replaced with 19 spurious amino acids. We interpret c.26_33dupAGGTGTCG as a pathogenic variant. - |
Primary familial hypertrophic cardiomyopathy;C4225408:Hypertrophic cardiomyopathy 25 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change creates a premature translational stop signal (p.Glu12Argfs*20) in the TCAP gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 156 amino acid(s) of the TCAP protein. This variant is present in population databases (rs778568339, gnomAD 0.1%). This premature translational stop signal has been observed in individual(s) with limb-girdle muscular dystrophy (PMID: 25055047, 27066551, 29797799). ClinVar contains an entry for this variant (Variation ID: 448649). This variant disrupts a region of the TCAP protein in which other variant(s) (p.Q53*) have been determined to be pathogenic (PMID: 10655062). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Autosomal recessive limb-girdle muscular dystrophy type 2G Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PVS1+PM3 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at